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Diquafosol is known as a purinergic P2Y2 receptor (P2Y2R) agonist that stimulates water and mucin
secretion from conjunctival epithelial cells and goblet cells, leading to tear ﬁlm stability in dry eye.
However, its effect on corneal epithelial healing has not yet been elucidated. The aim of the present study
was to evaluate the effect of diquafosol on corneal epithelial healing in vivo and on P2Y2R-related
downstream signaling pathways in vitro. We administered 3% diquafosol ophthalmic solution on
3 mm-diameter epithelial defects made in rat corneas and assessed the wound closure over time. Corneal
epithelial healing was signiﬁcantly accelerated in diquafosol-treated eyes compared to control eyes at 12
and 24 h. During wound healing, P2Y2R staining appeared stronger in the re-epithelized margin near the
wound defect. To evaluate whether diquafosol stimulates epidermal growth factor receptor/extracellular-
signal-regulated kinase (EGFR/ERK)-related cell proliferation and migration, simian virus 40-transfected
human corneal epithelial (THCE) cells were used for in vitro experiments. Cell proliferation was accel-
erated by diquafosol at concentrations from 20 to 200 mM during 48 h, but inhibited at concentrations
over 2000 mM. The intracellular calcium ([Ca2þ]i) elevation was measured in diquafosol (100 mM)-
stimulated cells using Fluo-4/AM ([Ca2þ]i indicator). [Ca2þ]i elevation was observed in diquafosol-
stimulated cells regardless of the presence of calcium in media, and suramin pretreatment inhibited
the calcium response. The effect of diquafosol on phosphorylation of EGFR, ERK and Akt, and cell
migration was determined by western blotting and in vitro cell migration assay. Diquafosol induced
phosphorylation of EGFR at 2 min post-stimulation, and phosphorylation of ERK at 5 min post-
stimulation. Phosphorylation of ERK was attenuated in cells pretreated with suramin or BAPTA/AM
([Ca2þ]i chelator), and partially with AG1478 (EGFR inhibitor). Likewise, diquafosol-treated cells showed
acceleration of gap closure in cell migration assay, which was inhibited by suramin, BAPTA/AM, AG1478,
and U0126 (MEK inhibitor). These studies demonstrate that diquafosol is effective in promoting corneal
epithelial wound healing and that this effect may result from ERK-stimulated cell proliferation and
migration via P2Y2R-mediated [Ca2þ]i elevation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The epithelial layer is the outermost layer to protect the tissue
against external stimuli such as mechanical or chemical injury or
infection by pathogens (Sack et al., 2001; Thoft et al., 1979). In the
cornea, the epithelium is crucial for maintenance of transparencylogy and Visual Science, Col-
ic University of Korea, Banpo-
ea.
r Ltd. This is an open access articleand clear vision by forming a smooth refractive surface covered
with tear ﬁlm (Argueso and Gipson, 2001; Pﬂugfelder et al., 2000).
Corneal epithelial defects must be rapidly restored to avoid path-
ogen invasion and further damage to the inner layer, which can lead
to corneal opacity and vision loss. Signiﬁcant efforts have been
made to understand the mechanisms of epithelial healing and to
identify the roles of various growth factors, including epidermal
growth factor (EGF), hepatocyte growth factor (HGF), and platelet
derived growth factor (PDGF) (Imanishi et al., 2000; Lu et al., 2001;
Yu et al., 2010).
Alongside these growth factors, extracellular nucleotides likeunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2007; Crooke et al., 2008, 2009; Dixon et al., 1999; Guzman-
Aranguez et al., 2013; Klepeis et al., 2004; Pintor et al., 2004;
Weinger et al., 2005). Although nucleotides, particularly ATP,
function as a universal energy source, they play a completely
different role in the extracellular compartment through the acti-
vation of receptors on the cell surface, P2 purinergic receptors
(P2Rs). P2Rs are divided into two families based on structural and
physiological differences: ionotropic P2X receptors (P2XRs), which
are nucleotide-gated ion channels, and metabotropic P2Y receptors
(P2YRs), which are G protein-coupled receptors (Junger, 2011).
Extracellular nucleotides activate P2YRs and induce downstream
signaling events including the mobilization of intracellular calcium
([Ca2þ]i) and the phosphorylation of EGF receptor (EGFR) and ERK,
which elicits the epithelial wound healing response (Boucher et al.,
2010; Gendaszewska-Darmach and Kucharska, 2011; Klepeis et al.,
2004; Pintor et al., 2004; Yin et al., 2007).
Diquafosol tetrasodium, a stabilized derivative of a UTP dimer
(P1,P4-bis[50-uridyl] tetraphosphate), was recently introduced for
treating dry eye. Diquafosol exhibits agonist activity on P2Y2 re-
ceptor (P2Y2R), a target receptor of UTP (Pendergast et al., 2001). At
the ocular surface, P2Y2R is expressed in the cornea, conjunctiva
including goblet cells, andmeibomian gland (Cowlen et al., 2003). In
the conjunctival epithelium, diquafosol accelerates ﬂuid efﬂux via
chloride channel activation after increasing [Ca2þ]i. In addition,
diquafosol reportedly facilitates the secretion of soluble mucin from
conjunctival goblet cells (Fujihara et al., 2002). These actions of
diquafosol ophthalmic solution promote tear ﬁlm stability on the
ocular surface, and clinical improvements in the treatment of dry
eye using diquafosol ophthalmic solution have been reported in
several studies (Matsumoto et al., 2012; Takamura et al., 2012).
However, no previous studies have evaluated the effects of
diquafosol on corneal epithelial wound healing. Activation of
P2Y2R triggers cell migration in different cell types (Bagchi et al.,
2005; Chaulet et al., 2001; Kaczmarek et al., 2005; Pillois et al.,
2002). In particular, extracellular nucleotides stimulate cell
migration in wounded corneal epithelium via P2Y2R activation
(Boucher et al., 2010; Yin et al., 2007). We hypothesized that
diquafosol, a UTP dimer, promotes corneal epithelial wound heal-
ing through P2Y2R activation and downstream signaling events. In
the present study, we demonstrated for the ﬁrst time that diqua-
fosol promotes corneal epithelial wound healing in vivo through
animal experiments and that this effect is mediated by downstream
signaling events including [Ca2þ]i elevation and phosphorylation of
EGFR and ERK.
2. Materials and methods
2.1. In vivo animal experiments
Male SpragueeDawley rats (10e12 weeks old, weighing
approximately 300 g) were used in the present study. All surgical
procedures were performed in the semi-pathogen free zone of our
animal care facility. All experiments were performed in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, and approved by the Institutional Animal Care and
Use Committee (IACUC) at the College of Medicine, The Catholic
University of Korea.
2.1.1. Corneal epithelial wound healing and topical application of
diquafosol on the cornea
We evaluated the effect of topical diquafosol on in vivo wound
healing of the rat corneal epithelium. Prior to surgery, rats were
anesthetized with 50 mg/kg tiletamine plus zolazepam (Zoletil®,
Virbac, Carros, France) and 15 mg/kg xylazine hydrochloride(Rompun®, Bayer, Leverkeusen, Germany) by intraperitoneal injec-
tion, and 0.5% proparacaine ophthalmic solution drops (Alcaine®,
Alcon, Fort Worth, TX, USA) were administered to the eyes. A round
epithelial debridement (3 mm in diameter) was produced at the
center of the cornea according to Saika's method with modiﬁcation
(Saika et al., 2000). Brieﬂy, the central corneal epithelium was
demarcated with a trephine (3 mm in diameter; Storz, St. Luis, MO,
USA) and subsequently removed using a burr (Algerbrush II, Preci-
sion Instruments Inc., Farmington Hills, MI, USA) under an operating
microscope (OPMI 1/S100, Carl Zeiss Meditec AG, Jena, Germany).
After injury to the epithelium, the eye was treated topically four
times a day with 3% diquafosol ophthalmic solution (DIQUAS®,
Santen Pharmaceutical Co., Ltd., Osaka, Japan) in treated rats (n ¼ 6)
or with vehicle (balanced salt solution [BSS], Alcon, Fort Worth, TX,
USA) in control rats (n ¼ 6) under inhalation anesthesia with iso-
ﬂurane (Forane, JW Pharmaceutical Co., Seoul, Korea). Surgery and
treatment were performed in one eye of treated and control rats.
Prophylactic antibiotic eye drops (levoﬂoxacin 0.5%; Cravit®, Santen
Pharmaceutical Co.) were also applied to the eye four times a day to
prevent infection. Images of the epithelial defects stained with
lissamine green dye (Green GloTM, HUB Pharmaceuticals, LLC,
Rancho Cucamonga, CA, USA) were taken at 0, 12, 24, and 36 h using
a digital camera equipped with an operating microscope (OPMI 1/
S100, Carl Zeiss Meditec). The area of the epithelial defect was
measured from images using ImageJ software (version 1.48, NIH,
Bethesda, Maryland, USA). The percentage of wound closure
(mean ± standard error of the mean [SEM]) was calculated at each
time point using the following equation: wound closure
(%) ¼ [(initial defect area  current defect area)/initial defect area].
2.1.2. P2Y2R immunoﬂuorescence staining of the corneal
epithelium
Immunoﬂuorescence staining of rat corneas was performed to
examine the expression patterns of P2Y2R in wounded and un-
wounded epithelium. At 12 h after wound inﬂiction, wounded
corneas and contralateral unwounded corneas were dissected from
treated rats (n ¼ 3) and control rats (n ¼ 3), and then ﬁxed in 4%
paraformaldehyde (PFA) overnight at 4 C. After washing with fresh
1 PBS, corneas were soaked in 30% sucrose for 24 h, and then
embedded in optimum cutting temperature (OCT) compound
(Tissue-Tek®, Sakura Fine Technical Co., Ltd., Tokyo, Japan) and
stored at 80 C. Eight-micrometer cryostat sections were placed
on silane-coated slides (5116-20F, Muto Pure Chemical, Tokyo,
Japan) and kept for 30 min at room temperature (RT) to air dry.
Samples on slides were rinsed in PBS and permeabilized in PBS
with 0.1% Triton-X (PBST) containing 10% donkey serum and 1%
bovine serum albumin (BSA; Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA, USA) for 1 h at RT. The slides were
incubated with primary antibodies in dilution buffer (0.1% PBST
with 1% BSA) overnight at 4 C, and subsequently incubated with
secondary antibodies in dilution buffer for 2 h at RT. The slides were
rinsed three times with PBS after each step. The slides were
mounted in mounting medium with 40,6-diamidino-2-
phenylindole (DAPI; Vectashield®, Vector Laboratories, Inc., Bur-
lingame, CA, USA) and examined with a confocal laser scanning
microscope (LSM710, Carl Zeiss Meditec). Goat anti-P2Y2R (1:200;
sc-15209, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used
as the primary antibody. Secondary antibodies (1:400; Alexa Fluor®
488, Life Technologies Inc., Carlsbad, CA, USA) were matched to the
host species of the primary antibodies.
2.2. In vitro experiments
2.2.1. Cell culture
To evaluate the cellular response to diquafosol in vitro, we used
Y.-S. Byun et al. / Experimental Eye Research 143 (2016) 89e97 91simian virus 40-transfected human corneal epithelial (THCE) cells,
kindly provided by Dr. Kaoru Araki-Sasaki, Osaka University, Osaka,
Japan (Araki-Sasaki et al., 1995). Cells were cultured in keratinocyte
serum-free medium (KSFM; 10724-011, Gibco®, Life Technologies
Inc.) containing supplements (50 mg/mL bovine pituitary extract,
5.0 ng/mL recombinant human epidermal growth factor; 37000-
015, Gibco®, Life Technologies Inc.) and 5 mg/mL gentamicin (15750-
078, Life Technologies Inc.) at 37 C in a humidiﬁed atmosphere at
5% CO2. The medium was changed every 3 days, and cells were
subcultured at 80e90% conﬂuence. Prior to each treatment, cells
were starved in KSFM without supplements for at least 12 h.
2.2.2. Cell proliferation/cytotoxicity assay
To determine the concentration of diquafosol to be used for the
in vitro experiments, cell proliferation/cytotoxicity assays were
performed using cell proliferation/cytotoxicity kits (CCK-8 kit and
WST-8 kit, Dojindo Molecular Technologies, Kumamoto, Japan)
according to the manufacturer's protocol. Suspended THCE cells
were seeded onto a 96-well plate (1  104 cells in 100 mL
supplement-free KSFM per well) and incubated with various con-
centrations of diquafosol (1.0e4.0 mM) for 48 h in a humidiﬁed
incubator (37 C, 5% CO2). KSFM only and KSFM containing re-
combinant human (rh)-EGF were used as positive and negative
controls, respectively. CCK-8 reagent was added to each well of the
plate after 30 min, 1, 2, 4, 8, 12, 24, or 48 h. After incubating for an
additional 2 h, wemeasured the absorbance values at 450 nm using
a microplate reader (VersaMax™, Molecular Devices, LLC, Sunny-
vale, CA, USA). All experiments were conducted in triplicate.
2.2.3. Measurement of [Ca2þ]i
THCE cell monolayers were grown in a 35-mm dish (Corning®
CellBIND®, Corning Inc., NY, USA) and incubated with KSFM con-
taining 4 mM Fluo-4/AM (intracellular calcium indicator; Molecular
Probes™, Life Technologies) for 30 min at 37 C in a humidiﬁed
incubator. After washing with Hank's balanced salt solution (HBSS;
#14170-112, Gibco®, Life Technologies Inc.), the cells were incu-
bated for an additional 30 min in four different media conditions
(1 mL): 1) KSFM only (containing 0.1 mM calcium), 2) KSFM with
suramin (200 mM), 3) calcium-free KSFM (#10725-018, Gibco®, Life
Technologies Inc.) only, and 4) calcium-free KSFM with suramin.
Then, diquafosol (200 mM) in loading medium (1 mL calcium-free
KSFM) was applied to the dishes. While diquafosol was loaded,
ﬂuorescence images (516 nm) were obtained sequentially at 1.0-s
intervals for 5 min using a live cell imaging inverted ﬂuorescence
microscope (Leica AF6000 Modular System, Leica Microsystems,
Wetzlar, Germany). Fluorescence intensity was expressed as rela-
tive ﬂuorescent units (F/F0) to initial ﬂuorescent intensity (F0) us-
ing ImageJ software (version 1.48, NIH).
2.2.4. Western blot analysis
P2Y2R and phosphorylation of EGFR, ERK1/2, and Akt were
quantiﬁed by western blot analysis. THCE cells at 80e90% conﬂu-
ence were starved in KSFM without supplements for 12 h, after
which they were incubated in KSFM or KSFM containing diquafosol
100 mM, suramin 200 mM (P2Y2 antagonist; SigmaeAldrich, St.
Louis, MO, USA), AG1478 5 mM (EGFR inhibitor; SigmaeAldrich),
BAPTA/AM 5 mM (intracellular calcium chelator, Santa Cruz
Biotechnology, Inc.), or U0126 10 mM (MEK inhibitor; Sigma-
eAldrich) to inhibit the respective signaling pathways. After each
treatment, THCE cells were lysed in RIPA buffer (20 mM TriseHCl,
pH 7.5, 0.1% [w/v] sodium lauryl sulfate, 0.5% [w/v] sodium deox-
ycholate,135mMNaCl, 1% [v/v] Triton X-100,10% [v/v] glycerol, and
2 mM EDTA) supplemented with a protease and phosphatase in-
hibitor cocktail (Thermo Scientiﬁc, Rockford, IL, USA). Cell lysates
were centrifuged at 14,000 rpm for 15 min and the supernatantswere collected. Total protein concentrations were determined via
BCA protein assay. The lysates were fractionated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and then
blotted onto a 0.45-mm nitrocellulose membrane (Amersham™,
Protran™, Premium, GE Healthcare Life Science, Munich, Ger-
many). The membrane was blocked in 1 Tris-buffered solution
with 0.1% Tween-20 (0.1% TBST) containing 5% BSA for 1 h at 4 C
with shaking, and then incubated with primary antibody in diluted
blocking buffer at 4 C overnight with shaking. To conﬁrm equal
protein loading, the blots were stripped and reprobed with anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody,
anti-EGFR antibody, or anti-ERK1/2 antibody. Bands were detected
using the ChemiDoc™ MP Imaging System (Bio-Rad, Hercules, CA,
USA). Densities of the bands were measured using ImageJ software
(version 1.48, NIH). All experiments were performed in triplicate.
The following antibodies were used: goat anti-P2Y2R (1:400; sc-
15209, Santa Cruz Biotechnology, Inc.), rabbit anti-EGFR (1:200;
sc-03, Santa Cruz Biotechnology, Inc.), mouse anti-ERK1/2 (1:2000;
#4696, Cell Signaling Technology, Danvers, MA, USA), mouse anti-
Akt (1:2000; #2920, Cell Signaling Technology), rabbit anti-
phospho-EGFR (1:2000; #2234, Cell Signaling Technology), rabbit
anti-phospho-ERK (1:2000; #4370, Cell Signaling Technology),
rabbit anti-phosphor-Akt (1:2000; #4060, Cell Signaling Technol-
ogy), and rabbit anti-GAPDH (1:400; ab8245, Abcam, Cambridge,
MA, USA).
2.2.5. Cell migration assay
In vitro cell migration assays were performed using the Oris™
96-well 2D assay kit (Platypus Technologies, LLC, Madison, WI,
USA) according to the manufacturer's protocol. This kit utilizes a
silicone stopper to cover a 2-mm-diameter zone and to restrict cell
seeding to the outer annular regions of the wells. Removal of the
stoppers reveals a 2-mm-diameter unseeded gap in the center of
each well into which the seeded cells may then migrate into during
each treatment. Unlike a scratch wound assay, this protocol pre-
vents the extracellular release of ATP and byproducts from
damaged cells. Brieﬂy, suspended cells (5  105 cells/mL) in 100 mL
KSFM were seeded in each well of a 96-well plate and incubated in
a humidiﬁed chamber (37 C, 5% CO2) for 18 h. All stoppers sealing
the central zone were removed and wells were gently washed with
PBS. After washing, fresh KSFM with various treatments was added
to each well. Cells were then incubated in a humidiﬁed incubator
(37 C, 5% CO2) and progression of cell migration was monitored.
After an additional 24-h incubation, cells were stained with 1%
toluidine blue, and images were taken using a digital charge-
coupled device (CCD; MC170-HD, Leica Microsystems) mounted
on a light microscope (CKX-41, Olympus). The percentage of gap
closure was calculated using ImageJ software (version 1.48, NIH).
2.3. Statistical analysis
Analysis of variance (ANOVA) was used to analyze differences
between groups. Differences were considered signiﬁcant when
P < 0.05. Mean values and SEM values are presented.
3. Results
3.1. In vivo animal experiments
3.1.1. Diquafosol promotes corneal epithelial wound healing in rats
After creating a 3-mm diameter epithelial defect on rat corneas
as described in Section 2.1.1, we compared the wound closure in
control eyes and diquafosol-treated eyes over 36 h (Fig. 1). The
diquafosol-treated eyes showed smaller defect sizes than controls
at 12 h and 24 h after treatment. At 36 h after diquafosol treatment,
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larity and punctate erosions were observed in some eyes. On the
other hand, control eyes showed more coarse and irregular surface
with punctate erosions, and epithelial defect remained in 50% of
control eyes (3/6) at 36 h. On image analysis, the percentages of
wound closure (%) in diquafosol-treated eyes were signiﬁcantly
higher at 12 and 24 h (63.4 ± 2.0% and 98.1 ± 1.1%, respectively)
than in control eyes (42.7 ± 2.5% and 82.3 ± 3.2%, respectively).
These results showed that topical diquafosol accelerates corneal
epithelial wound healing.
3.1.2. P2Y2R is dominantly stained in the wound margin of corneal
epithelium
We also observed the expression pattern of P2Y2R in wounded
and unwounded corneal epithelium by immunoﬂuorescence
staining (Fig. 2). P2Y2R was weakly stained in the normal epithe-
lium of unwounded corneas and in the healed multilayered
epithelium of diquafosol-treated corneas and control corneas,
whereas it was strongly stained in the epithelial margin around the
wound defect in diquafosol-treated corneas and control corneas.
There was no hypertrophy or abnormal polarity of healed epithe-
lium in diquafosol-treated corneas when wound closure was
complete (Appendix).
3.2. In vitro experiments
3.2.1. Diquafosol promotes THCE cell proliferation
Weperformed cell proliferation/cytotoxicity assays in THCE cellsFig. 1. The effect of topical diquafosol on epithelial wound healing of rat corneas. A 3-mm
n ¼ 6) or diquafosol (B, n ¼ 6) was applied topically four times a day. Images of epithelia
wounding. The size of the remaining epithelial defects was smaller in diquafosol-treated ey
epithelial defects were not found in diquafosol-treated eyes (B), whereas small defects werwith various concentrations of diquafosol to determine the range of
effective or toxic concentrations in vitro. The absorbance values
were measured at 30 min, 1, 2, 4, 8, 12, 24, and 48 h (Fig. 3). The
absorbance values of wells treated with 20, 50, 100, and 200 mM
diquafosol (0.605 ± 0.011, 0.632 ± 0.011, 0.602 ± 0.012, and
0.627 ± 0.044 at 24 h, and 0.643 ± 0.034, 0.677 ± 0.045,
0.681 ± 0.043, and 0.658 ± 0.026 at 48 h, respectively) were
signiﬁcantly higher than those of KSFM-only wells (0.473 ± 0.030
and 0.484 ± 0.007 at 24 and 48 h, respectively, all P < 0.05), and
were not lower than those of EGF-treated wells (0.658 ± 0.013 and
0.717 ± 0.013 at 24 and 48 h, respectively, all P < 0.05). On the other
hand, diquafosol at a concentration higher than 2000 mM signiﬁ-
cantly inhibited cell proliferation 12 h after incubation, compared
to KSFM only.
3.2.2. Diquafosol elicits [Ca2þ]i elevation in THCE cells
Wemeasured the ﬂuorescence intensity of serial images at 1.0-s
intervals for 5min to determine the change of [Ca2þ]i in diquafosol-
stimulated cells (Fig. 4). Diquafosol-stimulated cells in KSFM
showed a rapid increase in the ﬂuorescence intensity at 10 s post-
stimulation, a peak of intensity at around 30 s post-stimulation, and
a subsequent slow decrease to baseline (Fig. 4A). The relative in-
crease of ﬂuorescence intensity (DF/F0, %) reached to the maximum
value (32.5%) at 38.889 s (about 28 s post-stimulation) in KSFM.
Diquafosol-stimulated cells in calcium-free KSFM showed the same
pattern of response as those in KSFM, although the maximumvalue
(23.0% at 35 s post-stimulation) was slightly lower in the former.
Suramin pretreatment inhibited [Ca2þ]i elevation in diquafosol--diameter epithelial defect was produced at the center of the corneas, and vehicle (A,
l defects stained with lissamine green dye were obtained at 0, 12, 24, and 36 h after
es (B) at 12 and 24 h than in control eyes (A) at 12 and 24 h, respectively. At 36 h, no
e found in some control eyes (A).
Fig. 2. The immunoﬂuorescence expression pattern of P2Y2R in unwounded and wounded epithelium of rat corneas. The immunostaining pattern of P2Y2R (green) were observed
in the unwounded epithelium of healthy corneas (A), the wounded epithelium of control corneas (B) and diquafosol-treated corneas (C) with DAPI (blue) nuclear counterstaining (D,
E, and F, respectively). P2Y2R was weakly stained in the unwounded epithelium of healthy corneas (A, D). In contrast, P2Y2R was strongly stained in the re-epithelialized margin
(white arrow) of the wounded epithelium of control corneas (B, E) and diquafosol-treated corneas (C, F). Scale bars ¼ 20 mm.
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3.2.3. EGFR/ERK signaling is involved in diquafosol-induced
epithelial healing
We evaluated whether diquafosol promotes wound closure of
THCE cell monolayers and activates EGFR, ERK, and Akt signaling
pathways during wound closure. In the cell proliferation assay
described in Section 2.2.2, we found that 20e200 mM diquafosol
accelerated cell proliferation in THCE cells. Thus, 100 mM diquafosol
was used to perform western blot analysis and wound closure as-
says. At 2 min after incubation with diquafosol, phosphorylation of
EGFRwas observed and persisted until 10min. ERK phosphorylationFig. 3. The effect of diquafosol on cell proliferation in vitro. THCE cells (1  104 cells per we
various concentrations of diquafosol and cell proliferation was assayed using WST-8. Absorb
signiﬁcantly higher at 20, 50, 100, and 200 mM, compared to control with only KSFM (*P <
inhibited cell proliferation at concentrations above 2000 mM.was found from 5 to 30 min after incubation with diquafosol
(Fig. 5A). Phosphorylation of Akt, however, was not affected by
diquafosol stimulation. Phosphorylation of ERK by diquafosol was
not observed in cells pretreated for 30 min with suramin or BAPTA/
AM but was observed, albeit reduced, in cells pretreated with
AG1478, an EGFR inhibitor (Fig. 5B). The results of the in vitro cell
migration assay corresponded to these expression patterns in
western blot analysis (Fig. 5C). The percentage of gap closure in
diquafosol-treated cells (36.1 ± 2.0%) was signiﬁcantly higher than
that in non-treated cells (26.9 ± 2.0%, P < 0.05). The promotion of
gap closure by diquafosol was inhibited in cells pretreated with
suramin, BAPTA/AM, AG1478, andU0126 (percentage of gap closure:ll) were seeded into 96-well plates and starved for 12 h. Cells were then incubated at
ance values at 450 nm are given on the y-axis. After 24 h, the absorbance values were
0.05). Diquafosol promoted cell proliferation at concentrations from 20 to 200 mM, but
Fig. 4. Changes of [Ca2þ]i in THCE cells exposed to diquafosol. (A) After diquafosol was loaded to Fluo-4/AM-pretreated THCE cell monolayers, ﬂuorescence images at 516 nm were
sequentially obtained at an interval of 1.0 s for 5 min. Diquafosol was loaded at 10 s after image recoding was started (i). The consecutive images indicate the following time points;
ii; 22 s, iii; 32 s, iv; 43 s, v; 53 s, vi; 2 min, vii; 3 min, viii; 5 min after image recording. Fluorescence intensity (F) for each image was measured using ImageJ software, and the relative
change of ﬂuorescence intensity [(F  F0)/F0] was calculated to express the changes of [Ca2þ]i. [Ca2þ]i increased rapidly and reached its peak within 40 s from the time diquafosol
was loaded (black arrows) in the presence (solid line) and in the absence (dotted line) of calcium ion in KSFM (B, left panel). Suramin pretreatment (200 mM) abolished diquafosol-
induced [Ca2þ]i elevation in the presence and in the absence of calcium ion in KSFM (B, right panel). KSFM, keratinocyte serum-free medium; F, ﬂuorescence intensity at each time
point; F0, initial ﬂuorescence intensity. Scale bar ¼ 100 mm.
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P < 0.05).
4. Discussion
The effect of diquafosol on epithelial healing has not been re-
ported hitherto, although many previous studies have reported the
effects of diquafosol on tear ﬁlm and the clinical parameters related
to dry eye syndrome (Arita et al., 2013; Jumblatt and Jumblatt,1998;
Kaido et al., 2013; Kamiya et al., 2012; Koh et al., 2013, 2014; Kojima
et al., 2014; Matsumoto et al., 2012; Mori et al., 2014; Nakamura
et al., 2012; Shimazaki-Den et al., 2013; Takamura et al., 2012;
Tauber et al., 2004; Toda et al., 2014; Yokoi et al., 2014). Here, we
observed that diquafosol accelerates corneal epithelial healing in
experimental rats. There are two possible explanations for this.
First, diquafosol-induced tear ﬁlm stability may facilitate epithelial
healing. Second, diquafosol seems to play a role in corneal epithelial
cell proliferation and migration.
As for the ﬁrst mode of action, diquafosol is well known for
stabilizing the tear ﬁlm on the ocular surface through ﬂuid efﬂux
from the conjunctival epithelium (Li et al., 2001; Murakami et al.,
2004), secretion of soluble mucin by conjunctival goblet cells
(Murakami et al., 2003), and secretion of membrane-associated
mucin by the corneal epithelium (Fujihara et al., 2002). Tears nor-
mally contain growth factors that facilitate epithelial homeostasis
(Klenkler et al., 2007). However, there is no evidence thatdiquafosol stimulates tear production. Furthermore, two or three
days of wound closure is too short a period for the tear ﬁlm to be
signiﬁcantly affected by diquafosol.
Regarding the second mode of action, an effect of diquafosol on
corneal epithelial healing is expected based on previous evidence.
Diquafosol is a dinucleotide derivative of UTP, and has P2Y2R
agonist activity similar to that of UTP. In rabbit corneas, UTP pro-
motes epithelial wound healing (Pintor et al., 2004). The ATP
released from damaged cells also plays a critical role in the
epithelial wound healing process (Yin et al., 2007). Nucleotides
including ATP and UTP stimulate epithelial cell migration and
proliferation via P2YR-induced downstream signaling events
including Ca2þ elevation, and the phosphorylation of EGFR and ERK
(Boucher et al., 2010; Crooke et al., 2008; Mediero et al., 2008;
Muscella et al., 2004). In the present study, we found that diqua-
fosol stimulated cell proliferation and migration through the [Ca2þ]
ieEGFR/ERK signaling pathway in the samemanner as extracellular
nucleotides.
Through in vitro experiments using THCE cells, we conﬁrmed
that cell proliferationwas acceleratedwhenwe applied 20e200 mM
diquafosol over 48 h [Ca2þ]i was immediately elevated in
diquafosol-stimulated cells. Western blot analysis and cell migra-
tion assay revealed that 100 mM diquafosol induced EGFR phos-
phorylation at 2 min post-stimulation, followed by ERK
phosphorylation at 5 min post-stimulation. This ERK phosphory-
lation was attenuated by a P2Y2R antagonist, EGFR inhibitor, and
Fig. 5. Diquafosol activates EGFR/ERK signaling, which is [Ca2þ]i dependent in THCE cells. (A) The phosphorylation of EGFR, ERK, and Akt was assessed in THCE cells at indicated
times after diquafosol incubation by western blot analysis. (B) Serum- and growth factor-starved THCE cells were treated with 200 mM suramin, 5 mM AG1478, or 5 mM BAPTA/AM
for 30 min and further incubated with or without 100 mM diquafosol for 5 min. Cell lysates were immunoblotted with phospho-ERK1/2, ERK1/2, phospho-Akt, Akt, and P2Y2
antibody. GAPDH was used as a probe to normalize protein loading. The results are representative of three independent experiments. (C) Cell migration assay for 24 h was per-
formed to conﬁrm the result of western blot. The results are representative of three independent experiments. *P < 0.05.
Y.-S. Byun et al. / Experimental Eye Research 143 (2016) 89e97 95intracellular calcium chelator. These results indicate that diquafosol
accelerates corneal epithelial healing through [Ca2þ]i-mediated
EGFR/ERK signaling pathway by activating P2Y2R, in the same
manner as extracellular nucleotides.
Diquafosol induced ERK phosphorylation and promoted cell
migration in vitrowhen EGFR was blocked by AG1478, although the
response was reduced. This indicated the existence of an EGFR-
independent signaling pathway through which diquafosol stimu-
lates ERK. Other studies have shown that ERK phosphorylation may
occur independent of EGFR (Andreev et al., 2001; Boucher et al.,
2007; Montiel et al., 2006). In an EGFR-independent pathway,
P2Y2R initiates ERK activation by involving Shc and Grb2, or RAFTK
and PKC via [Ca2þ]i elevation (Soltoff et al., 1998). This result can be
explained as an alternate possibility supported by studies that have
shown that differential phosphorylation of speciﬁc EGFR tyrosine
residues, including 845, 1068, 1086, and 1173, occurs in response to
speciﬁc biologic activation (Moro et al., 2002).
In EGFR-dependent or -independent pathways, P2Y2R-
mediated ERK activation is calcium-dependent (Chuderland and
Seger, 2008). Our data also showed that intracellular calciumchelators potently inhibited diquafosol-induced ERK phosphoryla-
tion as well as cellular migration. P2Y2R, a G protein-coupled re-
ceptor, regulates mobilization of [Ca2þ]i from internal storage
through phospholipase C activation and production of inositol
triphosphate (IP3) and diacylglycerol (DAG) (Neary et al., 1999).
Previous studies have reported that P2Y2-mediated [Ca2þ]i eleva-
tion was not affected by the presence or absence of extracellular
calcium, and that it was inhibited by depletion of internal calcium
storage or blockage of secondmessengers (Green et al., 1997; Tovell
and Sanderson, 2008; Viana et al., 1998). In our study, diquafosol-
induced [Ca2þ]i elevation was blocked by suramin, a P2Y2R
antagonist, adding evidence that [Ca2þ]i elevation is triggered by
diquafosol acting on P2Y2R. The diquafosol-induced calcium
response was the same in the presence and absence of calcium in
media, although the peak intensity was slightly lower in calcium-
free KSFM, indicating that [Ca2þ]i was mobilized from internal
storage. We thought that the slightly reduced peak intensity was
probably due to the 30-min incubation in calcium-free KSFM prior
to diquafosol stimulation.
In summary, we demonstrated that topical diquafosol, a P2Y2R
Y.-S. Byun et al. / Experimental Eye Research 143 (2016) 89e9796agonist, promotes corneal epithelial wound healing in vivo. This
was supported by in vitro evidence that diquafosol induces cell
proliferation and migration through [Ca2þ]i-dependent ERK acti-
vation.We suggest that diquafosol may be helpful in treating ocular
surface disease with delayed healing, including desiccated ocular
surface in dry eye disease. Wound healing, however, is a compli-
cated process regulated by various factors including inﬂammation,
adhesion molecules, and extracellular matrix, besides proliferation
and migration. Therefore, further studies are needed to explore the
role of extracellular nucleotides and purinergic receptors in the
wound healing process.
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